Identification of chemical probes that specifically disrupt the GIV-Gi interface
鉴定特异性破坏 GIV-Gi 界面的化学探针
基本信息
- 批准号:8986801
- 负责人:
- 金额:$ 31.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-01-01 至 2017-12-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAutomationBehaviorBindingBiochemicalBiologicalBiological AssayBiological ProcessBiologyBostonBreastCancer ModelCell CommunicationCessation of lifeChemicalsCouplingDataDevelopmentDiseaseDisseminated Malignant NeoplasmDrug TargetingEnhancersEpithelialEsophagusEukaryotaFlowchartsFluorescence PolarizationFoundationsFutureG-Protein-Coupled ReceptorsGTP-Binding ProteinsGliomaGoalsGuanine Nucleotide Exchange FactorsHealthHeterotrimeric GTP-Binding ProteinsHomology ModelingHumanInterventionKnowledgeLaboratoriesMalignant NeoplasmsMammalian CellMarketingMeasuresMedicalMolecularMolecular TargetMusNeoplasm MetastasisNuclear Magnetic ResonanceOncogenicPathway interactionsPharmaceutical ChemistryPhenocopyPhysiologicalPoint MutationProcessProteinsPublic HealthPublishingQuality ControlRegulationResearchResearch PersonnelResourcesSignal TransductionSiteSite-Directed MutagenesisSpecificityTestingToxic effectTriageTumor Cell MigrationUniversitiesUp-RegulationValidationWorkYeastsanalogbasecolon cancer patientscounterscreendrug marketfollow-uphigh throughput screeninginhibitor/antagonistmedical schoolsneoplastic cellnovelnovel therapeuticsoverexpressionprotein activationprotein functionprotein protein interactionreceptorscreeningsuccesstargeted treatmenttissue culturetool
项目摘要
DESCRIPTION (provided by applicant): Signaling via heterotrimeric (henceforth trimeric) G proteins regulates most, if not all, physiological functions and its dysregulation is the cause of vast array of diseases. More than 30% of marketed drugs target G protein-coupled receptors (GPCRs), which are the classical activators of trimeric G proteins. We have recently identified a novel mechanism of signal transduction in which trimeric G proteins are activated by a cytoplasmic, non-receptor protein called GIV (aka Girdin) instead of by GPCRs. This mechanism has important biomedical implications because its upregulation is tightly associated with the development of metastasis. Despite that metastasis causes ~90% of cancer-related deaths, this process is still poorly understood and remains incurable. Thus, the existence of a novel, receptor-independent mechanism of G protein activation by GIV not only provides a new perspective on G protein signaling regulation but also opens new opportunities for pharmacological intervention. However, no existing chemical probe targets the GIV-G protein coupling. Our goal is to identify chemical probes that specifically inhibit the GIV-G protein interaction as research tools to further understand a novel mechanism of G protein signaling and its impact in disease. BACKGROUND: Previous work has established that a short linear motif of ~25 aa in GIV is responsible for its biological activity as a G protein activator (Guanine
nucleotide Exchange Factor, GEF) and as an enhancer of prometastatic behavior in tumor cells. Our published and unpublished data provide a wealth of structural information indicating that the GIV-G protein interaction is a tractable molecular interface that can be specifically targeted. Taken together, these results provide the proof of principle to consider the GIV-G?i interface a bona fide molecular target in signaling and cancer metastasis. Our hypothesis is that chemical probes that specifically inhibit the GIV-G?i interface will be valuable research tools to investigate a novel mechanism of G protein activation during metastasis and will lay the foundation for future targeted therapies. RESEARCH PLAN: All the assays required for this campaign have been established in our hands, including validation of the screen/ counter-screen assays in a pilot screen (Z'e0.7). In SA#1 we will carry out a high throughput screen (HTS) of >150,000 compounds using a fluorescence polarization (FP). Hits will be tested in a counter-screen assay based on AlphaScreen(R) to remove false positives and will be triaged by quality control of compounds and medicinal chemistry assessments. In SA#2 we will perform follow-up assays in yeast and mammalian cells to assess efficacy, specificity and toxicity. Filtered compounds and analogs optimized for potency will be eventually tested for their ability to block tumor cell migration as a surrogate measure of the bioactivity of the target (GIV-G?i) in metastasis. The HTS and assay automations will be performed at the ICCB-Longwood screening facility (Harvard Medical School) and the medicinal chemistry efforts required to triage hits and synthesize analogs will be carried by the co-investigator Aaron Beeler (Boston University).
描述(由申请人提供):通过异源三聚体(以下简称三聚体)G蛋白的信号传导调节大部分(如果不是全部)生理功能,其失调是大量疾病的原因。超过30%的上市药物靶向G蛋白偶联受体(gpcr),这是三聚体G蛋白的经典激活剂。我们最近发现了一种新的信号转导机制,其中三聚体G蛋白被一种称为GIV(又名Girdin)的细胞质非受体蛋白激活,而不是由gpcr激活。这一机制具有重要的生物医学意义,因为它的上调与转移的发生密切相关。尽管转移导致约90%的癌症相关死亡,但这一过程仍然知之甚少,并且仍然无法治愈。因此,一种新的、不依赖受体的GIV激活G蛋白的机制的存在,不仅为G蛋白信号调控提供了新的视角,也为药物干预开辟了新的机会。然而,目前还没有针对GIV-G蛋白偶联的化学探针。我们的目标是鉴定特异性抑制GIV-G蛋白相互作用的化学探针作为研究工具,以进一步了解G蛋白信号传导的新机制及其在疾病中的影响。背景:先前的研究已经确定,GIV中~ 25aa的短线性基序是其作为G蛋白激活剂(鸟嘌呤)的生物活性的原因
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mikel Garcia-Marcos其他文献
Mikel Garcia-Marcos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mikel Garcia-Marcos', 18)}}的其他基金
Versatile and high-fidelity optical biosensor platforms for GPCR signaling
用于 GPCR 信号传导的多功能高保真光学生物传感器平台
- 批准号:
10679863 - 财政年份:2023
- 资助金额:
$ 31.1万 - 项目类别:
Direct chemogenetic control of heterotrimeric G protein signaling
异源三聚体 G 蛋白信号传导的直接化学遗传学控制
- 批准号:
10590217 - 财政年份:2022
- 资助金额:
$ 31.1万 - 项目类别:
Non-canonical activation of heterotrimeric G protein signaling in vivo
异源三聚体 G 蛋白信号传导的体内非典型激活
- 批准号:
10220082 - 财政年份:2019
- 资助金额:
$ 31.1万 - 项目类别:
Non-canonical activation of heterotrimeric G protein signaling in vivo
异源三聚体 G 蛋白信号传导的体内非典型激活
- 批准号:
10461747 - 财政年份:2019
- 资助金额:
$ 31.1万 - 项目类别:
Non-canonical activation of heterotrimeric G protein signaling in vivo
异源三聚体 G 蛋白信号传导的体内非典型激活
- 批准号:
9914590 - 财政年份:2019
- 资助金额:
$ 31.1万 - 项目类别:
Non-canonical activation of heterotrimeric G protein signaling in vivo
异源三聚体 G 蛋白信号传导的体内非典型激活
- 批准号:
10018921 - 财政年份:2019
- 资助金额:
$ 31.1万 - 项目类别:
Non-canonical activation of heterotrimeric G protein signaling in vivo
异源三聚体 G 蛋白信号传导的体内非典型激活
- 批准号:
10581960 - 财政年份:2019
- 资助金额:
$ 31.1万 - 项目类别:
Targeting of non-canonical G protein signaling with small molecules
用小分子靶向非经典 G 蛋白信号传导
- 批准号:
10180984 - 财政年份:2018
- 资助金额:
$ 31.1万 - 项目类别:
Alternative mechanisms of signaling via trimeric G proteins
通过三聚体 G 蛋白传递信号的替代机制
- 批准号:
10374905 - 财政年份:2014
- 资助金额:
$ 31.1万 - 项目类别:
相似海外基金
Treecle - data and automation to unlock woodland creation in the UK to achieve net zero
Treecle - 数据和自动化解锁英国林地创造以实现净零排放
- 批准号:
10111492 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
SME Support
STTR Phase II: Optimized manufacturing and machine learning based automation of Endothelium-on-a-chip microfluidic devices for drug screening applications.
STTR 第二阶段:用于药物筛选应用的片上内皮微流体装置的优化制造和基于机器学习的自动化。
- 批准号:
2332121 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
Cooperative Agreement
Improving access to AI automation to support new digital offerings within Professional/Financial Services
改善对人工智能自动化的访问,以支持专业/金融服务中的新数字产品
- 批准号:
10095096 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
Collaborative R&D
SBIR Phase II: Radar-based Building Automation
SBIR 第二阶段:基于雷达的楼宇自动化
- 批准号:
2335079 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
Cooperative Agreement
Next-generation automation and PAT implementation for QbD and enhanced approaches for cell and gene therapy
QbD 的下一代自动化和 PAT 实施以及细胞和基因治疗的增强方法
- 批准号:
10087446 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
Collaborative R&D
Cost-Effective, AI-driven Automation Technology for Cell Culture Monitoring: Boosting Efficiency and Sustainability in Industrial Biomanufacturing and Streamlining Supply Chains
用于细胞培养监测的经济高效、人工智能驱动的自动化技术:提高工业生物制造的效率和可持续性并简化供应链
- 批准号:
10104748 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
Launchpad
Sustainable Remanufacturing solution with increased automation and recycled content in laser and plasma based process (RESTORE)
可持续再制造解决方案,在基于激光和等离子的工艺中提高自动化程度和回收内容(RESTORE)
- 批准号:
10112149 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
EU-Funded
Automation and cost reduction of the hardware and software components of a novel indoor sustainable vertical growing solution
新型室内可持续垂直种植解决方案的硬件和软件组件的自动化和成本降低
- 批准号:
83007861 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
Innovation Loans
Artificial intelligence coupled to automation for accelerated medicine design
人工智能与自动化相结合,加速药物设计
- 批准号:
EP/Z533038/1 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
Research Grant
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 31.1万 - 项目类别:
Collaborative R&D